Dyadic Appoints Chief Business Officer to Executive Leadership Team
JUPITER, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),...
Day: November 9, 2021
POINT Biopharma and IONETIX Announce Ac-225 Supply Agreement
Supply agreement enables development of POINT’s next-generation Ac-225-based radioligand therapies.INDIANAPOLIS and TORONTO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma...
SCYNEXIS Announces Successful Completion of Phase 1 Trial Evaluating Intravenous (IV) Formulation of Ibrexafungerp
Safety and tolerability of new liposomal IV formulation confirmed to reach target exposure in single ascending dose (SAD) and multiple...
Maple Leaf Green World Inc. and Biolinear Complete JV to Develop New Nano Enhanced CBG Products
CALGARY, Alberta, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Maple Leaf Green World Inc. (“Maple Leaf” or the “Company”), (CSE: MGW)...
Rubius Therapeutics to Participate in Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically...
Healthcare Triangle, Inc. to Present at the Emerging Growth Conference on November 10, 2021
PLEASANTON, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Healthcare Triangle Inc., (Nasdaq: HCTI) (“HCTI” or the "Company"), a leading provider...
vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update
HIGH POINT, N.C., Nov. 09, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third...
Vor to Present New Data on its Cell and Genome Engineering Platform at SITC Annual Meeting
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today...
Evolus Announces Participation in November Investment Conferences
NEWPORT BEACH, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric...
Surgery Partners, Inc. Announces Pricing of $279.0 million Public Offering of Common Stock
BRENTWOOD, Tenn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (Nasdaq: SGRY) (“Surgery Partners”) today announced the pricing of...
Preclinical Data Supporting Therapeutic Potential of Surface Oncology’s Lead Clinical Programs, SRF617 and SRF388, Presented at the Society for Immunotherapy of Cancer 2021 Annual Meeting
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that...
Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Cancer 2021 Annual Meeting
HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the presentation...
Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details
Data from Phase IIb AIPAC, including final Overall Survival data, reported in a separate announcementEncouraging Objective Response Rate (ORR) of...
aTyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, ATYR2810, on Tumor Associated Macrophages at the Society for Immunotherapy of Cancer Annual Meeting
Findings provide key insights into ATYR2810’s potential mechanism of action, including ability to modulate key immune cells involved in tumor...
Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
PRESS RELEASE RESS RELEASE Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at...
Agenus to Participate in Fireside Chat at the B. Riley Fall 2021 Growth Biotech Best Ideas Series
LEXINGTON, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of...
Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to be Presented at 2021 Society for Immunotherapy of Cancer Annual Meeting
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baselineBatiraxcept has been...
Quipt Continues National Expansion With Closing of Strategic Acquisition in Central Illinois and Ongoing Business Momentum as Respiratory Equipment Demand Remains Elevated Into Fiscal Q1 2022
$2.5 Million in Annualized Revenues, 25% Projected Adjusted EBITDA Margin Post Integration, and Adds Over 3,700 Active Patients Quipt Has...
Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights
- Oral Presentation at European Society for Gene and Cell Therapy (ESGCT) demonstrated ability to generate potent anti-cancer cell therapy...
Ultimovacs’ SITC2021 Data Shows Enduring T cell Response for UV1 Combination in Melanoma
UV1 vaccine combined with ipilimumab induced immune responses in 91% of melanoma patientsImmune responses persist and are detectable up to...
